Viela Bio (VIE) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights
May 13, 2020 4:16 PM EDTCompany to host investor conference call and webcast today at 5:00 pm ET
GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq: VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today reported financial results and provided program highlights for the first quarter ended March 31, 2020.
With the PDUFA date for our lead product candidate, inebilizumab, approaching in about one month, we are nearing another major company milestoneour first potential U.S. regulatory approval, said Bing Yao, Ph.D., Chief Executive Officer at Viela Bio. In anticipation,... More
